FDA Expands CoreValve TAVR Indication to Intermediate-Risk Patients FDA Expands CoreValve TAVR Indication to Intermediate-Risk Patients

The expanded indication to include treatment of patients with severe aortic stenosis at intermediate risk for surgery is based on the pivotal SURTAVI data reported this March.FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Cardiology News Alert Source Type: news